Jiafeng Zou

Mr. Jiafeng Zou

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YLYingni Lv
Yingni Lv
MRMengjiao Ren
Mengjiao Ren
MYMin Yao
Min Yao
JZJiafeng Zou
Jiafeng Zou
SFSiqi Fang
Siqi Fang
FGFeng Gao
Feng Gao

1 June 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XSXiaowei Shi
Xiaowei Shi
RMRui Ma
Rui Ma
YLYanping Lu
Yanping Lu
YCYing Cheng
Ying Cheng
XFXudong Fan
Xudong Fan
JPJi-Gang Piao
Ji-Gang Piao

11 March 2020 in ACS Sustainable Chemistry & Engineering
Verified
Journal Article
Closed access
JZJiafeng Zou
Jiafeng Zou
DBDandan Bao
Dandan Bao
RMRui Ma
Rui Ma
ZZZhihong Zhu
Zhihong Zhu
XCXiaojie Chen
Xiaojie Chen
JPJi-Gang Piao
Ji-Gang Piao

1 April 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
WYWenjie Yao
Wenjie Yao
ZXZhishi Xu
Zhishi Xu
JSJiang Sun
Jiang Sun
JLJingwen Luo
Jingwen Luo
DWDr. Yinghui Wei
Dr. Yinghui Wei
JZJiafeng Zou
Jiafeng Zou

20 October 2023 in Nanomaterials
Verified
Journal Article
Open access
PDF file
JWJunshan Wang
Junshan Wang
MYMin Yao
Min Yao
JZJiafeng Zou
Jiafeng Zou
WDWenxing Ding
Wenxing Ding
MSMingyue Sun
Mingyue Sun
FGFeng Gao
Feng Gao
Though the anti-miR-301a (anti-miR) is a promising treatment strategy for inflammatory bowel disease (IBD), the degradability and the poor targeting of the intestine are a familiar issue. This study aimed to develop a multifunctional oral nanoparticle delivery system loaded with anti-miR for improving the targeting ability and the therapeutic efficacy. The HA-CS/ES100/PLGA nanoparticles (HCeP NPs) were prepared using poly (lactic-co-glycolic acid) copolymer (PLGA), enteric material Eudragit®S100 (ES100), chitosan (CS), and hyaluronic acid (HA). The toxicity of nanoparticles was investigated via the Cell Counting Kit-8, and the cellular uptake and inflammatory factors of nanoparticles were further studied. Moreover, we documented the colon targeting and pharmacodynamic properties of nanoparticles. The nanoparticles with uniform particle size exhibited pH-sensitive release, favorable gene protection, and storage stability. Cytology experiments showed that anti-miR@HCeP NPs improved the cellular uptake through HA and reduced pro-inflammatory factors. Administering anti-miR@HCeP NPs orally to IBD mice markedly reduced their pro-inflammatory factors levels and disease activity indices. We also confirmed that anti-miR@HCeP NPs mostly accumulated in the colon site, and effectively repaired the intestinal barrier, as well as relieved intestinal inflammation. The above nanoparticle is a candidate of the treatment for IBD due to its anti-inflammatory properties.